Press Releases Johnson & Johnson BOERSE MUENCHEN

Equities

JNJ

US4781601046

Market Closed - BOERSE MUENCHEN Other stock markets 15:59:28 2024-05-23 EDT			5-day change	1st Jan Change
138.4 ^EUR	-2.33%		+0.84%	+0.10%

08:03pm	Some of the biggest splits in Corporate America	RE
05-22	Cancer victims sue Johnson & Johnson over 'fraudulent' bankruptcies	RE

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Proposed Class Action Filed by Six Law Firms Alleging Series of Fraudulent Transfers by Johnson & Johnson in Talc Litigation	05-22	BU
Engitix Announces Appointment of Matthew Edwards Ph.D., as SVP Discovery and Emma Huang Ph.D., as VP Data Sciences	05-22	AQ
TREMFYA (guselkumab) QUASAR Maintenance Study in UC met its primary endpoint and all major secondary endpoints, including highly statistically significant rates of endoscopic remission	05-21	AQ
Novel biologic could offer ulcerative colitis symptomatic remission	05-21	AQ
MAIA Biotechnology (NYSE: MAIA) Makes Strategic Moves: Key Presentations, New Funding, and Leadership Changes Drive Innovation	05-21	AQ
Johnson & Johnson : to Participate in the 2024 RBC Capital Markets Global Healthcare Conference Transcript	05-17	PU
Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment	05-16	BU
Johnson & Johnson : to Participate in the BofA Securities Health Care Conference Transcript	05-15	PU
Johnson & Johnson : to Participate in the 2024 RBC Capital Markets Global Healthcare Conference Press Release	05-15	PU
Johnson & Johnson : to Participate in the BofA Securities Health Care Conference Press Release	05-15	PU
Johnson & Johnson to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference	05-08	BU
Intravesical drug delivery system exhibits bladder cancer benefit	05-07	AQ
Johnson & Johnson - Phase 2 data for ERLEADA plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localized prostate cancer show 100% biochemical free recurrence rate	05-06	AQ
Johnson & Johnson Highlights Commitment to Transform Treatment of Retinal Diseases at ARVO 2024	05-06	AQ
Johnson & Johnson - TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non-muscle-invasive bladder cancer	05-06	AQ
Johnson & Johnson submits regulatory applications to European Medicines Agency for TREMFYA (guselkumab) for treatment of patients with ulcerative colitis and Crohn's disease	05-03	AQ
Johnson & Johnson Announces Plan by its Subsidiary, LLT Management LLC, to Resolve All Current and Future Ovarian Cancer Talc Claims Through a Consensual 'Prepackaged' Reorganization	05-03	AQ
Johnson & Johnson : 2024 First-Quarter Press Release & Supplemental Schedules (April 16, 2024)	05-02	PU
Johnson & Johnson : Announces Plan by its Subsidiary, LLT Management LLC, to Resolve All Current and Future Ovarian Cancer Talc Claims Through a Consensual “Prepackaged” Reorganization Press Release	05-02	PU
J&J subsidiary proposes paying about $6.48B over 25 years to settle talc ovarian cancer lawsuits	05-01	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 12:30 pm